Citicoline Dosage: 250-500mg for Focus/Memory, More for Stroke
Educational summary — not medical advice. Citicoline has no established RDA or upper limit, and its healthy-adult evidence base is small and short-term. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The honest answer
The two indexed cognition trials used 250–500 mg/day — McGlade 2019 tested 250mg or 500mg/day for 28 days in adolescent males, Nakazaki 2021 tested 500mg/day for 12 weeks in older adults with age-associated memory impairment. That is far below the stroke-trial doses: ICTUS reached 2000 mg/day orally after an IV loading phase, Cotroneo 2013 used 1,000mg/day for 9 months, and Spiers 1996 used 1,000–2,000mg/day. A retail 250mg capsule does not replicate stroke-trial dosing — and the stroke trial itself was null for recovery.
The dose depends on which evidence you're chasing
Citicoline doesn't have one settled retail dose, and the honest reason is that the trials behind it split into populations with very different doses and very different levels of evidence. In the healthy/near-healthy cognition literature, McGlade 2019 randomized adolescent males to 250mg or 500mg Cognizin/day for 28 days, and Nakazaki 2021 randomized older adults with age-associated memory impairment to 500mg Cognizin/day for 12 weeks. Both are Kyowa Hakko-funded, both are short-duration, and neither tested doses above 500mg/day.
The stroke and vascular-cognitive literature is a different story. ICTUS (Dávalos 2012) treated acute ischemic stroke patients with 1,000mg IV every 12 hours for 3 days, then 2×500mg oral every 12 hours (2000mg/day) through 6 weeks — and found no significant recovery benefit over placebo. Cotroneo 2013 (open-label, not blinded) used 500mg twice daily (1,000mg/day) for 9 months in patients with mild vascular cognitive impairment. Spiers 1996 used 1,000mg/day initially, then 2,000mg/day in a crossover subphase, in older adults screened to exclude dementia. None of these doses were tested for long-term safety in healthy adults, and the highest-dose, most rigorous trial (ICTUS) was null for its primary outcome.
| Use case | Dose studied | Result |
|---|---|---|
| Attention & psychomotor speed, adolescent males | 250mg or 500mg/day, 28 days | Attention ↑ (p=0.02), psychomotor speed ↑ (p=0.03) vs placebo (McGlade 2019, n=75, Kyowa Hakko-funded) |
| Episodic memory, older adults with AAMI | 500mg/day, 12 weeks | Secondary episodic-memory outcome significantly ↑ (p=0.0025) vs placebo (Nakazaki 2021, n=100, Kyowa Hakko-funded) |
| Acute ischemic stroke recovery | 2000mg/day oral (after IV loading), 6 weeks | Global recovery at 90 days NOT significantly different vs placebo — NULL (Dávalos 2012 / ICTUS, n=2,298, independent/academic) |
| Mild vascular cognitive impairment | 1,000mg/day, 9 months | MMSE improved vs control — open-label, NOT randomized/blinded, weaker design (Cotroneo 2013, n=349) |
| Verbal memory in older adults | 1,000–2,000mg/day | Delayed recall improved only in a post-hoc subgroup with inefficient baseline memory, not the full sample (Spiers 1996, n=95) |
Is your dose in the cognition-trial range?
Enter your total daily citicoline mg (add up all servings if you take more than one). This checks your dose against the 250-500mg/day cognition-trial range and the much higher stroke/vascular-trial doses — it does not tell you whether citicoline works, only where your dose falls relative to what's actually been studied.
How to think about your dose
- 250–500 mg/day is the cognition-trial reference range from the two indexed trials that tested near-healthy populations — not the much higher stroke-trial figure.
- More is not automatically better. No trial in this evidence base directly compared cognition outcomes at 250mg vs 500mg vs 1,000mg+ in the same healthy population — don't assume a 1,000mg retail product outperforms a 250mg one on cognition.
- The 2000mg/day ICTUS dose is disease-population, clinical-protocol evidence — and that trial found no significant recovery benefit. A higher dose is not a shortcut to a stronger effect that wasn't demonstrated at any dose in that trial.
- Short-term tolerability looks good across ICTUS (n=2,298, 6 weeks) and Cotroneo (n=349, 9 months) at doses well above retail cognition products, with no severe adverse events reported — but no long-term (6-month+) safety data exists specifically for healthy adults at 250-500mg/day.
- Pregnant or breastfeeding? No data exists for citicoline in this population — check with a clinician because of the absence of data, not a specific toxicity signal.
Picks at the cognition-trial dose
Full ranking, including the Cognizin-vs-generic axis, is on best citicoline.
500mg/serving, Cognizin-branded, cheapest per mg of all six tracked products.
250mg/serving, Cognizin-branded, lowest total sticker price to try it.
As an Amazon Associate we earn from qualifying purchases. Of 6 products tracked; ranked by cost per mg, never commissions.
Frequently asked questions
How much citicoline should I take per day?
The indexed cognition trials used 250-500mg/day. The ICTUS stroke-trial dose (2000mg/day) is a disease-population figure, not a healthy-adult target — and that trial was null.
Why did the stroke trial use so much more citicoline?
ICTUS used a clinical-intervention protocol (IV loading, then 2000mg/day oral) in acute stroke patients — disease treatment dosing, not a wellness dose, and it did not outperform placebo.
Is there a citicoline RDA or upper limit?
No. Citicoline is not an essential nutrient, so there's no RDA/AI/UL. Reference points are the 250-500mg cognition-trial range and the much higher disease-population doses — neither is a regulatory ceiling.
Does a 250mg retail capsule replicate stroke-trial dosing?
No — it's roughly one-eighth of the 2,000mg/day ICTUS oral dose, and that trial found no significant stroke-recovery benefit at any point in its protocol.
Related
- Citicoline: what it is & who it's for
- Best citicoline — ranked by cost per mg, Cognizin vs. generic
- Citicoline for focus, attention & memory
- Does citicoline work — and vs. alpha-GPC
Sources
- McGlade EC, et al. "The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males." J Atten Disord. 2019 (Epub 2015). PMID: 26179181 (250mg/500mg, 28 days; Kyowa Hakko-funded).
- Nakazaki E, et al. "Citicoline and Memory Function in Healthy Older Adults." J Nutr. 2021. PMID: 33978188 (500mg, 12 weeks; Kyowa Hakko-funded).
- Dávalos A, et al. "Citicoline in the treatment of acute ischaemic stroke (ICTUS trial)." The Lancet. 2012. PMID: 22691567 (2000mg/day oral phase; NULL for global recovery).
- Cotroneo AM, et al. "Effectiveness and safety of citicoline in mild vascular cognitive impairment (IDEALE study)." Clin Interv Aging. 2013. PMID: 23403474 (1,000mg/day, 9 months; open-label).
- Spiers PA, et al. "Citicoline improves verbal memory in aging." Arch Neurol. 1996. PMID: 8624220 (1,000-2,000mg/day).
- Full product dataset: /citicoline/cost-by-brand.json (CC BY 4.0).